首页 > 最新文献

Uroonkoloji Bulteni-Bulletin of Urooncology最新文献

英文 中文
Active Surveillance in Prostate Cancer 癌症前列腺癌的主动监测
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-12-20 DOI: 10.4274/uob.820
V. Izol, N. Akdoğan
{"title":"Active Surveillance in Prostate Cancer","authors":"V. Izol, N. Akdoğan","doi":"10.4274/uob.820","DOIUrl":"https://doi.org/10.4274/uob.820","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"127-132"},"PeriodicalIF":0.2,"publicationDate":"2017-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49274827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Presentation of Germ Cell Neoplasia: Persistant Müllerian Duct Syndrome 罕见的生殖细胞瘤的表现:持续性<s:1>勒氏管综合征
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/UOB.825
A. Beksac, M. Dönmez, Ç. Aydın, D. Baydar, M. Yazıcı, A. Ergen, B. Akdogan
Persistent Müllerian duct syndrome (PMDS) is defined as the presence of Müllerian remnants in a phenotypically and karyotypically male (1). PMDS is caused either by the lack of anti-Müllerian hormone, receptor insensitivity or a defect in the timing of the release of Müllerian inhibiting factor (MIF). PMDS is regarded as a form of pseudohermaphroditism due to presence of uterus and is shown to be inherited autosomal recessively (2). Although it is predominantly seen in pediatric age group presenting as undescended testis with or without inguinal hernia, it might be presented as an inguinal or intraabdominal mass in adulthood (3). Herein we report 2 cases of PMDS with review of the literature. Case Presentations
持续性马勒氏管综合征(PMDS)被定义为在表型和核型男性中存在马勒氏残余(1)。PMDS是由缺乏抗马勒氏激素、受体不敏感或马勒氏抑制因子(MIF)释放时间缺陷引起的。由于存在子宫,PMDS被认为是假雌雄同体的一种形式,并被证明是常染色体隐性遗传(2)。虽然它主要见于儿科年龄组,表现为伴有或不伴有腹股沟疝的隐睾,但在成年期可能表现为腹股沟或腹内肿块(3)。在此,我们报告了2例PMDS并回顾了文献。案例展示
{"title":"A Rare Presentation of Germ Cell Neoplasia: Persistant Müllerian Duct Syndrome","authors":"A. Beksac, M. Dönmez, Ç. Aydın, D. Baydar, M. Yazıcı, A. Ergen, B. Akdogan","doi":"10.4274/UOB.825","DOIUrl":"https://doi.org/10.4274/UOB.825","url":null,"abstract":"Persistent Müllerian duct syndrome (PMDS) is defined as the presence of Müllerian remnants in a phenotypically and karyotypically male (1). PMDS is caused either by the lack of anti-Müllerian hormone, receptor insensitivity or a defect in the timing of the release of Müllerian inhibiting factor (MIF). PMDS is regarded as a form of pseudohermaphroditism due to presence of uterus and is shown to be inherited autosomal recessively (2). Although it is predominantly seen in pediatric age group presenting as undescended testis with or without inguinal hernia, it might be presented as an inguinal or intraabdominal mass in adulthood (3). Herein we report 2 cases of PMDS with review of the literature. Case Presentations","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"101-104"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47902449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do Length and Tumor Grades of Positive Surgical Margin Have an Impact on Biochemical Recurrence After Prostatectomy 前列腺切除术后阳性切缘的长度和肿瘤分级对生化复发有影响吗
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/UOB.859
M. Koparal, C. Acar, Betul Ogut, E. Tokat, Fatih Bicaklioglu, I. Gönül, A. Batur, T. Sözen
{"title":"Do Length and Tumor Grades of Positive Surgical Margin Have an Impact on Biochemical Recurrence After Prostatectomy","authors":"M. Koparal, C. Acar, Betul Ogut, E. Tokat, Fatih Bicaklioglu, I. Gönül, A. Batur, T. Sözen","doi":"10.4274/UOB.859","DOIUrl":"https://doi.org/10.4274/UOB.859","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"86-91"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48622242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Sex and Age Differences on Pathology Results in Primary Bladder Cancer Patients 性别和年龄差异对原发性膀胱癌患者病理结果的影响
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/uob.857
H. Türk, Sıtkı Ün, Batuhan Ergani
{"title":"The Effect of Sex and Age Differences on Pathology Results in Primary Bladder Cancer Patients","authors":"H. Türk, Sıtkı Ün, Batuhan Ergani","doi":"10.4274/uob.857","DOIUrl":"https://doi.org/10.4274/uob.857","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"81-85"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47986569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Relationship Between Human Papilloma Virus and Bladder Cancer 人乳头瘤病毒与癌症的关系
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/UOB.556
O. Inci, E. Taştekin, H. Akdere
{"title":"Relationship Between Human Papilloma Virus and Bladder Cancer","authors":"O. Inci, E. Taştekin, H. Akdere","doi":"10.4274/UOB.556","DOIUrl":"https://doi.org/10.4274/UOB.556","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"92-94"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46984735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer? 前列腺癌的尿液、血清和组织生物标志物有何新进展?
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/uob.620
H. Şahin, M. Çetinkaya, H. Deliktaş
{"title":"What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer?","authors":"H. Şahin, M. Çetinkaya, H. Deliktaş","doi":"10.4274/uob.620","DOIUrl":"https://doi.org/10.4274/uob.620","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"43 1","pages":"95-100"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Primary Adrenal Lymphoma: A Case Report 原发性肾上腺淋巴瘤1例报告
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/uob.876
I. Kazaz, Ayhan Arslan, Nergiz Erkut, O. Kutlu
{"title":"Primary Adrenal Lymphoma: A Case Report","authors":"I. Kazaz, Ayhan Arslan, Nergiz Erkut, O. Kutlu","doi":"10.4274/uob.876","DOIUrl":"https://doi.org/10.4274/uob.876","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"105-107"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49029673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer 对膀胱癌具有潜在免疫治疗活性的布鲁分枝杆菌提取物
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/UOB.905
Zeliha Ertürk, Esra Büber, H. Özen, Ö. Çelikbıçak, B. Salih, N. Acan
Amaç: Lokal ve sistemik yan etkilerine rağmen, yüksek riskli kasa invaziv olmayan mesane kanserinde (KİOMK) Bacillus Calmette-Guérin (BCG) uygulanması altın standart tedavidir. Biz mesane kanseri tedavisi için canlı suşlar yerine daha az toksik ve daha güçlü terapötik ajanlar geliştirmeyi hedefledik. Gereç ve Yöntem: İmmünostimülan ve sitotoksik aktiviteleri BCG ile benzerlik gösteren patojen olmayan Mycobacterium brumae suşu kullanıldı. Bakteriler ısı muamelesinden sonra sonike edildi. Sulu çözeltiyle ve asetonla ekstre edilerek hazırlanmış örnekler ters faz ve kuvvetli iyon değiştirici kolonlar kullanılarak yüksek performanslı sıvı kromatografisi uygulandı. Örneklerin tümör nekroz faktörü-α (TNF-α) uyarıcı aktiviteleri ve matriks-yardımlı lazer desorpsiyon-iyonlaştırmalı-kütle spektrometri çıktıları incelendi. Bulgular: Sonuç olarak, m/z oranları 1800 ve 3600 dolayındaki iki bileşenin TNF-α uyarıcı aktiviteden sorumlu olabileceği ortaya çıkarıldı. Sonuç: Bu bileşenler KİOMK tedavisi için yeni ajanlar geliştirme potansiyeline sahiptir. Anahtar Kelimeler: Mycobacterium brumae, kasa invaziv olmayan mesane kanseri, yüksek performanslı sıvı kromatografisi, matriks-yardımlı lazer desorpsiyon-iyonlaştırmalı kütle spektrometri, tümör nekroz faktörü-α Objective: Immunotherapy with intravesical Bacillus Calmette-Guérin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain. Materials and Methods: Non-pathogenic Mycobacterium brumae strains resembling BCG in immunostimulating and cytotoxic activities were used. The bacteria were sonicated after heat treatment. Samples prepared by aqueous solution and acetone were subjected to high performance liquid chromatography on reverse phase and strong ion exchange columns. Tumour necrosis factor-α (TNF-α) stimulating activities and the matrixassisted laser desorption/ionization-mass spectroscopy findings of the samples were analysed. Results: As a result, it was revealed that two components, m/z ratios around 1800 and another around m/z 3600 could be responsible for TNF-α stimulating activity. Conclusion: These components have a potential to develop of new agents for NMIBC treatment.
目的是将卡氏杆菌(BCG)应用于非高危储存癌症的金标准治疗,尽管存在局部和全身副作用。我们的目标是开发毒性更小、更强的治疗剂,而不是癌症治疗的活水。Gereçve Yöntem:Il mmünostimülan ve sitotoksik aktiviteleri BCG ile benzerlik gösteren patojen olmayan分枝杆菌brumae suşu kullanıldı。细菌经过热处理后就消失了。高效液相色谱法已应用于反相离子交换柱和强力离子交换柱的水分辨率和asetone提取样品。研究了肿瘤坏死因子α(TNF-α)预警活性和基质辅助激光解吸电离质谱的实例。事件:因此,1800至3600之间的两种成分被证明是TNF-α警告活性的原因。结果:这些成分有能力开发用于KIOMK治疗的新药物。关键词:布鲁马分枝杆菌、无创性美沙拉烷癌症、高效液相色谱法、基质辅助激光解吸电离质谱法、肿瘤坏死因子-α,尽管它有局部和系统的副作用。我们的目标是开发比活菌株毒性更小、更强大的治疗剂来治疗膀胱癌症。材料和方法:使用具有类似BCG的免疫刺激和细胞毒性活性的非致病性布鲁马分枝杆菌菌株。热处理后对细菌进行超声处理。用水溶液和丙酮制备的样品在反相和强离子交换柱上进行高效液相色谱。分析了样品的肿瘤坏死因子-α(TNF-α)刺激活性和基质辅助激光解吸/电离质谱结果。结果:两组分,m/z比值在1800左右和m/z比值约在3600左右,可能对TNF-α的刺激活性起作用。结论:这些成分具有开发新的NMIBC治疗药物的潜力。
{"title":"Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer","authors":"Zeliha Ertürk, Esra Büber, H. Özen, Ö. Çelikbıçak, B. Salih, N. Acan","doi":"10.4274/UOB.905","DOIUrl":"https://doi.org/10.4274/UOB.905","url":null,"abstract":"Amaç: Lokal ve sistemik yan etkilerine rağmen, yüksek riskli kasa invaziv olmayan mesane kanserinde (KİOMK) Bacillus Calmette-Guérin (BCG) uygulanması altın standart tedavidir. Biz mesane kanseri tedavisi için canlı suşlar yerine daha az toksik ve daha güçlü terapötik ajanlar geliştirmeyi hedefledik. Gereç ve Yöntem: İmmünostimülan ve sitotoksik aktiviteleri BCG ile benzerlik gösteren patojen olmayan Mycobacterium brumae suşu kullanıldı. Bakteriler ısı muamelesinden sonra sonike edildi. Sulu çözeltiyle ve asetonla ekstre edilerek hazırlanmış örnekler ters faz ve kuvvetli iyon değiştirici kolonlar kullanılarak yüksek performanslı sıvı kromatografisi uygulandı. Örneklerin tümör nekroz faktörü-α (TNF-α) uyarıcı aktiviteleri ve matriks-yardımlı lazer desorpsiyon-iyonlaştırmalı-kütle spektrometri çıktıları incelendi. Bulgular: Sonuç olarak, m/z oranları 1800 ve 3600 dolayındaki iki bileşenin TNF-α uyarıcı aktiviteden sorumlu olabileceği ortaya çıkarıldı. Sonuç: Bu bileşenler KİOMK tedavisi için yeni ajanlar geliştirme potansiyeline sahiptir. Anahtar Kelimeler: Mycobacterium brumae, kasa invaziv olmayan mesane kanseri, yüksek performanslı sıvı kromatografisi, matriks-yardımlı lazer desorpsiyon-iyonlaştırmalı kütle spektrometri, tümör nekroz faktörü-α Objective: Immunotherapy with intravesical Bacillus Calmette-Guérin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain. Materials and Methods: Non-pathogenic Mycobacterium brumae strains resembling BCG in immunostimulating and cytotoxic activities were used. The bacteria were sonicated after heat treatment. Samples prepared by aqueous solution and acetone were subjected to high performance liquid chromatography on reverse phase and strong ion exchange columns. Tumour necrosis factor-α (TNF-α) stimulating activities and the matrixassisted laser desorption/ionization-mass spectroscopy findings of the samples were analysed. Results: As a result, it was revealed that two components, m/z ratios around 1800 and another around m/z 3600 could be responsible for TNF-α stimulating activity. Conclusion: These components have a potential to develop of new agents for NMIBC treatment.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"70-76"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47606928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience 多西紫杉醇化疗治疗去势抵抗性前列腺癌的疗效:单中心经验
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-09-28 DOI: 10.4274/UOB.821
Evren Süer, N. Hamidi, M. Gökçe, S. Baltacı
77 ©Telif Hakkı 2017 Üroonkoloji Derneği / Üroonkoloji Bülteni Galenos Yayınevi tarafından basılmıştır Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Nurullah Hamidi, Atatürk Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye Tel.: +90 312 508 22 58 E-mail: dr.nhamidi86@gmail.com ORCID-ID: orcid.org/0000-0002-6825-1813 Ge liş Ta ri hi/Re cei ved: 06.02.2017 Ka bul Ta ri hi/Ac cep ted: 31.05.2017 Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment option is docetaxel based chemotherapy (DBC). In this study, we aimed to present our retrospective series. Materials and Methods: We retrospectively evaluated the patients who received DBC in our clinic between January 2004 and December 2015. Totally 162 patients who are histopathologically diagnosed with PCa, clinically and radiographically demonstrated metastasis and fit to European Association of Urology CRPC criteria were included to the study. DBC was given for one day for a 3-week period, with a dose of 75 mg/m2. Prostate specific antigen (PSA) response is evaluated for ≥50% decrease in the PSA level measured at the first day of the chemotherapy. Additionally, overall survival is evaluated. Results: The majority of the patients had high stage and high Gleason score PCa. Of them totally 76% were a primary metastatic. Two-year overall survival was 18.5%, median overall survival was 15.2 months in the study population. PSA response was demonstrated in 59.2% of the patients. In multivariate analysis, the CRPC development time was found to be an independent prognostic factor both for overall survival and PSA response. Conclusion: DBC is still the main treatment option for CRPC patients for long term and successful outcomes.
77©Telif hakkyi 2017 Üroonkoloji Derneği / Üroonkoloji b lteni Galenos Yayınevi tarafından basılmıştır Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Nurullah Hamidi博士,atat rk Eğitim ve Araştırma Hastanesi, Üroloji Kliniği,土耳其安卡拉 rkiye电话:+90 312 508 22 58 E-mail: dr.nhamidi86@gmail.com orcidid - id: orcid.org/0000-0002-6825-1813 Ge liza Ta ri hi/接收日期:06.02.2017 Ka bul Ta ri hi/Ac接收日期:31.05.2017目的:前列腺癌(PCa)是全球第二常见的癌症类型。前列腺癌的死亡率主要与去势抵抗性前列腺癌(CRPC)的发展有关。在这些患者中,主要的治疗选择是基于多西他赛的化疗(DBC)。在这项研究中,我们旨在展示我们的回顾性系列。材料和方法:我们回顾性评估2004年1月至2015年12月在我诊所接受DBC治疗的患者。162例经组织病理学诊断为前列腺癌,临床和影像学证实转移,符合欧洲泌尿外科协会CRPC标准的患者被纳入研究。DBC给药1天,为期3周,剂量为75 mg/m2。在化疗第一天测量的PSA水平下降≥50%时评估前列腺特异性抗原(PSA)反应。此外,评估总生存期。结果:多数患者为高分期、高Gleason评分PCa。其中76%为原发性转移。研究人群的两年总生存率为18.5%,中位总生存率为15.2个月。59.2%的患者出现PSA应答。在多变量分析中,发现CRPC发展时间是总生存和PSA反应的独立预后因素。结论:DBC仍是CRPC患者长期有效的主要治疗选择。
{"title":"The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience","authors":"Evren Süer, N. Hamidi, M. Gökçe, S. Baltacı","doi":"10.4274/UOB.821","DOIUrl":"https://doi.org/10.4274/UOB.821","url":null,"abstract":"77 ©Telif Hakkı 2017 Üroonkoloji Derneği / Üroonkoloji Bülteni Galenos Yayınevi tarafından basılmıştır Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Nurullah Hamidi, Atatürk Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye Tel.: +90 312 508 22 58 E-mail: dr.nhamidi86@gmail.com ORCID-ID: orcid.org/0000-0002-6825-1813 Ge liş Ta ri hi/Re cei ved: 06.02.2017 Ka bul Ta ri hi/Ac cep ted: 31.05.2017 Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment option is docetaxel based chemotherapy (DBC). In this study, we aimed to present our retrospective series. Materials and Methods: We retrospectively evaluated the patients who received DBC in our clinic between January 2004 and December 2015. Totally 162 patients who are histopathologically diagnosed with PCa, clinically and radiographically demonstrated metastasis and fit to European Association of Urology CRPC criteria were included to the study. DBC was given for one day for a 3-week period, with a dose of 75 mg/m2. Prostate specific antigen (PSA) response is evaluated for ≥50% decrease in the PSA level measured at the first day of the chemotherapy. Additionally, overall survival is evaluated. Results: The majority of the patients had high stage and high Gleason score PCa. Of them totally 76% were a primary metastatic. Two-year overall survival was 18.5%, median overall survival was 15.2 months in the study population. PSA response was demonstrated in 59.2% of the patients. In multivariate analysis, the CRPC development time was found to be an independent prognostic factor both for overall survival and PSA response. Conclusion: DBC is still the main treatment option for CRPC patients for long term and successful outcomes.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"6 1","pages":"77-80"},"PeriodicalIF":0.2,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70978856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Imaging in Testicular Cancer Diagnosis, Staging and Follow-up 影像在睾丸癌诊断、分期及随访中的作用
IF 0.2 Q4 ONCOLOGY Pub Date : 2017-06-15 DOI: 10.4274/UOB.694
N. Voyvoda, Bekir Voyvoda, Özden Çamurdan
{"title":"The Role of Imaging in Testicular Cancer Diagnosis, Staging and Follow-up","authors":"N. Voyvoda, Bekir Voyvoda, Özden Çamurdan","doi":"10.4274/UOB.694","DOIUrl":"https://doi.org/10.4274/UOB.694","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"51-56"},"PeriodicalIF":0.2,"publicationDate":"2017-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48751041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Uroonkoloji Bulteni-Bulletin of Urooncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1